Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

Int J Med Sci 2022; 19(3):486-487. doi:10.7150/ijms.71614 This issue

Erratum

PRMT4 promotes hepatocellular carcinoma progression by activating AKT/mTOR signaling and indicates poor prognosis: Erratum

Peng Du, Kaifeng Luo, Guoyong Li, Jisheng Zhu, Qi Xiao, Yong Li✉, Xingjian Zhang✉

Department of General Surgery, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, China.

✉ Corresponding authors: Xingjian Zhang, Department of General Surgery, The First Affiliated Hospital of Nanchang University, No. 17 Yongwai Zheng Street, Nanchang, Jiangxi 330006, China. E-mail: lfyzhangbocom. Yong Li, Department of General Surg More

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Citation:
Du P, Luo K, Li G, Zhu J, Xiao Q, Li Y, Zhang X. PRMT4 promotes hepatocellular carcinoma progression by activating AKT/mTOR signaling and indicates poor prognosis: Erratum. Int J Med Sci 2022; 19(3):486-487. doi:10.7150/ijms.71614. Available from https://www.medsci.org/v19p0486.htm

File import instruction

Corrected-article in Int J Med Sci, Volume 18, 3588

©2022 Ivyspring International Publisher. Terms of use